{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/LTRN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T09:52:09.538Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11916,"canonical_name":"Lantern Pharma Inc.","cik":"0001763950","uei":null,"lei":null,"duns":null,"ticker":"LTRN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":12,"clinical":2},"count":14,"timeline":[{"ts":"2026-06-18","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Lantern Pharma Inc. — 2026-06-18","url_slug":"/sec/cik-0001763950/effect/9999999995-26-002072","accession_number":"9999999995-26-002072","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"S-1","title":"S-1 — Lantern Pharma Inc. — 2026-06-12","url_slug":"/sec/cik-0001763950/s-1/0001493152-26-028460","accession_number":"0001493152-26-028460","importance":65},{"ts":"2026-06-02","kind":"sec.filing","form_type":"8-K","title":"8-K — Lantern Pharma Inc. — 2026-06-02","url_slug":"/sec/cik-0001763950/8-k/0001493152-26-026696","accession_number":"0001493152-26-026696","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"D","title":"D — Lantern Pharma Inc. — 2026-05-21","url_slug":"/sec/cik-0001763950/d/0001493152-26-024786","accession_number":"0001493152-26-024786","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Lantern Pharma Inc. — 2026-05-15","url_slug":"/sec/cik-0001763950/schedule-13d-a/0001813314-26-000008","accession_number":"0001813314-26-000008","importance":70},{"ts":"2026-05-15","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Lantern Pharma Inc. — 2026-05-15","url_slug":"/sec/cik-0001763950/10-q/0001493152-26-023740","accession_number":"0001493152-26-023740","importance":45},{"ts":"2026-05-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Lantern Pharma Inc. — 2026-05-15","url_slug":"/sec/cik-0001763950/8-k/0001493152-26-023758","accession_number":"0001493152-26-023758","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Lantern Pharma Inc. — 2026-05-14","url_slug":"/sec/cik-0001763950/8-k/0001493152-26-023200","accession_number":"0001493152-26-023200","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Lantern Pharma Inc. — 2026-05-14","url_slug":"/sec/cik-0001763950/4/0001493152-26-023083","accession_number":"0001493152-26-023083","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"424B5","title":"424B5 — Lantern Pharma Inc. — 2026-05-14","url_slug":"/sec/cik-0001763950/424b5/0001493152-26-022895","accession_number":"0001493152-26-022895","importance":30},{"ts":"2026-05-12","kind":"sec.insider.p","reporter":"KEYSER D JEFFREY","title":"","shares":48544,"price_per_share":2.06,"usd_value":100001,"security_title":"Common stock, $0.001 par value","importance":50.10000064},{"ts":"2026-05-12","kind":"sec.insider.p","reporter":"Schalop Lee Troy","title":"","shares":48544,"price_per_share":2.06,"usd_value":100001,"security_title":"Common stock, $0.001 par value","importance":50.10000064},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Lantern Pharma Inc.","title":"Study of LP-184 in Patients With Advanced Solid Tumors","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05933265","excerpt":"[\"Advanced Solid Tumor\",\"Metastatic Solid Tumor\",\"GBM\",\"TNBC - Triple-Negative Breast Cancer\",\"NSCLC\",\"Pancreatic Adenocarcinoma\",\"DDR Gene Mutation\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Lantern Pharma Inc.","title":"Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06132503","excerpt":"[\"Relapsed or Refractory Lymphomas\",\"Advanced Solid Tumor\"]","importance":30}]}